Intuitive Surgical/$ISRG
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Intuitive Surgical
Intuitive develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 11,000 da Vinci systems in hospitals worldwide, with more than 6,600 installations in the US and a growing number in emerging markets.
- Ticker
- $ISRG
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 17,021
- Headquarters
- Sunnyvale, United States
- Website
- www.intuitive.com
ISRG Metrics
BasicAdvanced
$156B
54.33
$8.27
1.46
-
Price and volume
Market cap
$156B
Beta
1.46
52-week high
$603.88
52-week low
$328.57
Average daily volume
2.5M
Financial strength
Current ratio
4.157
Quick ratio
3.326
Profitability
EBITDA (TTM)
4,528.8
Gross margin (TTM)
66.64%
Net profit margin (TTM)
25.54%
Operating margin (TTM)
31.78%
Effective tax rate (TTM)
17.85%
Revenue per employee (TTM)
$680,000
Management effectiveness
Return on assets (TTM)
11.88%
Return on equity (TTM)
17.93%
Valuation
Price to earnings (TTM)
54.333
Price to revenue (TTM)
13.714
Price to book
9.75
Price to tangible book (TTM)
10.23
Price to free cash flow (TTM)
44.132
Free cash flow yield (TTM)
2.27%
Free cash flow per share (TTM)
10.186
Growth
Revenue change (TTM)
20.45%
Earnings per share change (TTM)
9.47%
3-year revenue growth (CAGR)
19.11%
10-year revenue growth (CAGR)
16.02%
3-year earnings per share growth (CAGR)
24.86%
10-year earnings per share growth (CAGR)
14.92%
What the Analysts think about ISRG
Analyst ratings (Buy, Hold, Sell) for Intuitive Surgical stock.
Analyst projections of the future price of Intuitive Surgical stock.
Bulls say / Bears say
Q3 revenue rose 22% to $3.05bn as da Vinci procedures grew 14% and Ion procedures 31%. With 84% of revenue recurring, higher use of the installed base can keep driving repeat sales of instruments, accessories and services. (Intuitive Surgical)
Intuitive placed 546 da Vinci systems in Q3, up 28% year on year, including 315 of its newer da Vinci 5 systems. More than 2,000 da Vinci 5 systems are now installed, supporting an upgrade cycle and future procedure capacity. (Intuitive Surgical, The Motley Fool)
Ion offers a fast-growing second platform: procedures rose 31% and its installed base grew 21% year on year in Q3. This gives Intuitive another avenue for growth alongside da Vinci. (Intuitive Surgical)
Management expects pricing changes, including longer-life instruments and a China price reduction, to lower da Vinci instruments-and-accessories revenue per procedure by 3–5% once fully introduced. That puts pressure on a major recurring revenue stream. (The Motley Fool)
U.S. da Vinci procedure growth was 10% in Q3, half the 20% growth outside the U.S., and management narrowed its 2026 outlook to 14–15%. It is also watching the effects of reduced health-insurance support on patient demand. (MedTech Dive, Intuitive Surgical)
A Ninth Circuit ruling revived a separate antitrust case over Intuitive’s control of robot instruments and servicing, sending it back for further proceedings. This leaves legal and potential business-practice uncertainty beyond the $450m customer settlement announced in October. (CourtListener, The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 10 Nov 2026.
ISRG Financial Performance
Revenues and expenses
ISRG Earnings Performance
Company profitability
Upcoming events
No upcoming events
ISRG News
AllArticlesVideos
Funds containing ISRG
AllUSDEURGBP
Fund name | Fund size | $ISRG weighting |
|---|---|---|
iShares Automation & Robotics£RBTX | $5.2B | 3.16% |
iShares Automation & Robotics$RBOT | $5.2B | 3.16% |
iShares Automation & Robotics€2B76 | $5.2B | 3.16% |
L&G ROBO Global Robotics and Automation£ROBG | $1.7B | 2.36% |
L&G ROBO Global Robotics and Automation$ROBO | $1.7B | 2.36% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.